Ways to unravel the clinical potential of carbon ions for head and neck cancer reirradiation: dosimetric comparison and local failure pattern analysis as part of the prospective randomized CARE trial

Thomas Held1,2,3,4,5*, Thomas Tessonnier1,2,3,4,5, Henrik Franke1,2,3, Sebastian Regnery1,2,3, Lukas Bauer1,2,3, Katharina Weusthof1,2,3, Semi Harrabi1,2,3,4,5,6, Klaus Herfarth1,2,3,4,5,6, Andrea Mairani1,2,3,4,5,6,7, Jürgen Debus1,2,3,4,5,6 and Sebastian Adeberg1,2,3,4,5,6

Abstract

Background: Carbon ion radiotherapy (CIRT) yields well-known biophysical advantages [1] compared to photons yet what are key clinical benefits and potential pitfalls for patients with recurrent head and neck cancer? Although recent studies reported excellent outcomes with CIRT in various open-access studies, randomized studies for the reirradiation setting are pending. The aim of the current project was to evaluate potential clinical benefits and drawbacks of CIRT compared to volumetric modulated arc therapy (VMAT) in recurrent head and neck cancer.

Methods: Dose-volume parameters and local failure patterns of CIRT compared to VMAT were evaluate in 16 patients from the randomized CARE trial on head and neck cancer reirradiation.

Results: Despite an increased target dose, CIRT resulted in significantly reduced organ at risk (OAR) dose across all patients (−8.7% Dmean). The dose-volume benefits were most pronounced in the brainstem (−20.7% Dmax) and the optic chiasma (−13.0% Dmax). The most frequent local failure was type E (extraneous; 50%), followed type B (peripheral; 33%) and type A (central; 17%). In one patient with type A biological and/or dosimetric failure after CIRT, mMKM dose recalculation revealed reduced target coverage.

Conclusions: CIRT resulted in highly improved critical OAR sparing compared to VMAT across all head and neck cancer reirradiation scenarios despite an increased prescription dose. Local failure pattern analysis revealed further potential CIRT specific clinical benefits and potential pitfalls with regard to image-guidance and biological dose-optimization.

Keywords: Heavy ions, Carbon ion radiotherapy, Squamous cell carcinoma, Reirradiation, Head and neck cancer, Local control, Dosimetric analysis, Pattern of failure, Re-radiotherapy, VMAT

*Correspondence: thomas.held@med.uni-heidelberg.de

© The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
recurrent tumor sites [2], high-level evidence of clinical superiority is pending. Besides careful patient selection, the complex reirradiation setting requires a high-precision approach to enhance the balance of tumor control and toxicity. Therefore, the randomized controlled CARE trial [3], comparing CIRT with volumetric modulated arc therapy (VMAT) for reirradiation of head and neck cancer, was recently initiated.

Building on previous photon reirradiation studies [4, 5], modern conformal radiation techniques such as stereotactic body radiation therapy improved outcomes primarily in early-stage recurrent tumors [6]. In reality, most inoperable recurrences are further impeded by tissue changes from previous treatments, making VMAT the standard of care [7]. Both proton [8] and in particular carbon ion reirradiation [9, 10] could further enhance dose escalation while reducing normal tissue complication probabilities. However, sophisticated radiobiological models [11] are required to calculate the relative biological effectiveness (RBE)-weighted dose of carbon ions for different tissues, treatment parameters and endpoints. Biological dose calculation based on the local effect model [12, 13] (LEM I) depends primarily on the clinical \( \alpha/\beta \) value from the linear quadratic model, the absorbed dose and the underlying complex mixed radiation field of carbon ions to predict the local RBE. More recent RBE-models, in particular the modified microdosimetric kinetic model [14] (mMKM), revealed trends towards superior RBE prediction in low/midrange LET conditions [15] but outcome analysis in clinical trials is pending. Moreover, treatment delivery uncertainties of scanned carbon beams, mitigated by image-guidance and robust optimization, are crucial for treatment planning.

In the current project, dose-volume parameters of CIRT and VMAT were compared for target volumes and organs at risk (OAR) in different reirradiation scenarios. Further implications for target volume delineation and dose optimization were evaluated as part of a pattern of local failure analysis. Thereby, the aim of the current project was to unravel potential clinical benefits and pitfalls of CIRT compared to VMAT in patients with recurrent head and neck cancer.

**Methods**

**Patient selection**

After approval by the regional ethics committee (S-708/2018), the prospective randomized CARE trial was initiated in 2020. In this study [3], patients with recurrent head and neck cancer receive reirradiation with either CIRT or VMAT. We selected the first 16 patients enrolled in the study to compare dose-volume parameters and evaluate local failure patterns.

**Reirradiation treatment planning**

Treatment planning was conducted according to the CARE protocol [3] using RayStation 10A (RaySearch Laboratories, Stockholm, Sweden). Delineation of OAR was performed in line with consensus guidelines [16]. The gross tumor volume (GTV) was defined based on contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI) and surgery/pathology reports. The clinical target volume (CTV) included the macroscopic tumor and/or tumor bed with a margin of 3–5 mm. A margin of 2–3 mm was added for the planning target volume (PTV). No elective nodal irradiation was performed.

All patients treated with VMAT received 60 Gy in 30 fractions (5 fractions/week). Patients that received CIRT were treated with 51 Gy (RBE) in 17 fractions (5–6 fractions/week) or 51–60 Gy (RBE) if the radiotherapy (RT) interval was ≥ 2 years. Additional 20–30% total cumulative dose to OAR was only allowed after a minimum of two years [17, 18]. Calculation of the RBE-weighted dose of CIRT was based on LEM I [12, 19] with an \( \alpha/\beta \) value of 2 Gy for the target and OAR, in line with the clinical standard at our institution.

Image-guidance consisted of daily orthogonal X-rays for CIRT [20] with additional CT scans in selected patients or daily kV cone-beam CTs for VMAT. If required, the treatment plan was adapted at the discretion of the radiation oncologist team. Treatment delivery for CIRT was performed with a raster scanning delivery at a synchrotron-based facility using active energy selection [21], while using a 6 MV linear accelerator for VMAT treatment.

**Dosimetric analysis and comparison**

For all patients that received VMAT, an additional CIRT treatment planning in line with the CARE protocol was performed and vice versa. Dose-volume parameters were extracted for the target volumes and most relevant OAR. Target volume coverage was assessed based on the volume (in %) receiving ≥ 95% of the prescribed dose (V95%). The dose distribution was evaluated using the homogeneity index [22] for the CTV, where the ideal value is zero. The maximum (Dmax) and mean (Dmean) dose and for all OAR in addition the dose applied to 1%, 5% (D1), 5% (D5) and 10% (D10) was specified. All CIRT treatment plans were scaled down to 51 Gy (RBE) total dose to facilitate comparison. The applied dose was specified by the equivalent dose in 2 Gy fractions (EQD2) for all patients. All dose reductions were specified further in percent of 60 Gy EQD2 for both CIRT and VMAT to facilitate comparisons. Predefined clinical goals for reirradiation, depending on the previous RT, were evaluated for target volumes and OAR according to the study.

**Dosimetric analysis and comparison**

For all patients that received VMAT, an additional CIRT treatment planning in line with the CARE protocol was performed and vice versa. Dose-volume parameters were extracted for the target volumes and most relevant OAR. Target volume coverage was assessed based on the volume (in %) receiving ≥ 95% of the prescribed dose (V95%). The dose distribution was evaluated using the homogeneity index [22] for the CTV, where the ideal value is zero. The maximum (Dmax) and mean (Dmean) dose and for all OAR in addition the dose applied to 1%, 5% (D1), 5% (D5) and 10% (D10) was specified. All CIRT treatment plans were scaled down to 51 Gy (RBE) total dose to facilitate comparison. The applied dose was specified by the equivalent dose in 2 Gy fractions (EQD2) for all patients. All dose reductions were specified further in percent of 60 Gy EQD2 for both CIRT and VMAT to facilitate comparisons. Predefined clinical goals for reirradiation, depending on the previous RT, were evaluated for target volumes and OAR according to the study.
protocol. Mean dose volume histograms were generated for all regions of interest.

**Pattern of local failure evaluation**
In patients with local failure after reirradiation, the recurrent macroscopic tumor was contoured on the diagnostic CT/MRI, mapped to the planning CT and deformed manually (rGTV). In three patients, more than one rGTV was delineated. Based on the rGTV, the recurrence volume, Dmean, Dmax and D95% were evaluated. Modified from Mohamed et al. [23], local failure was evaluated by centroid (central voxel of rGTV with 2 mm margin) location in relation to the CTV. Failures were classified in type A (central CTV; D95% rGTV ≥ 95% prescribed dose), type B (peripheral CTV; D95% rGTV < 95% prescribed dose) and type E (outside CTV). In patients with type A local failure after CIRT, dose recalculation based on mMKM was conducted.

**Statistical methods**
Statistical analysis was performed using R version 4.1.0 (www.r-project.org). For each dose-volume parameter, the mean and standard deviation was compared. The Wilcoxon signed-rank test was applied to evaluate differences based on paired samples (CIRT vs. VMAT). A p value < 0.05 was considered statistically significant.

**Results**

**Patient and treatment characteristics**
All patients had locally advanced recurrent tumors, most of them high-grade (63%). The median age prior to reirradiation was 59 years (range 49–73 years) and the median RT interval was 3.3 years (range 0.7–28.0 years). The majority were male patients (69%) and/or active smokers (63%). Most patients had squamous cell carcinoma (81%) and received definitive RT (75%). The mean GTV, CTV and PTV were 28.9, 69.5 and 107.5 ccm and the mean cumulative EQD2 was 130.1 Gy. A total of nine patients received CIRT and seven VMAT. Relevant patient characteristics are summarized in Table 1.

**Dosimetric analysis of target volumes and organs at risk**
The mean EQD2 in the CTV was 63.6 Gy for CIRT and 60.2 Gy for VMAT (p < 0.001). Target volume coverage was comparable with both modalities. The V95% of the GTV, CTV and PTV was not significantly different between CIRT and VMAT. The homogeneity index of the CTV was reduced with CIRT compared to VMAT (p = 0.003). Target volume and OAR dose metrics of CIRT vs. VMAT are shown in Fig. 1A. Further data is shown in the appendix (Additional file 1: Tab. S3).

Despite the significantly higher prescribed dose in the CTV, the mean Dmean throughout all evaluated OAR was significantly reduced with CIRT compared to VMAT (p < 0.001). A pronounced decrease of mean dose occurred among others in the ipsilateral inner ear (−8.2 Gy EQD2; 13.7%), the brainstem (−7.2 Gy EQD2; −7.2 Gy EQD2; −7.2 Gy EQD2).

---

**Table 1** Patient characteristics, tumor classification and treatment of all patients with recurrent head and neck cancer

| Pat | ReRT | Age (y) | KPS (%) | Localization | Type | Concept | T | N | M | R | G | Interval (y) | ReRT EQD2 (Gy) | Cum. EQD2 (Gy) | CTV (ccm) |
|-----|------|--------|---------|-------------|------|---------|---|---|---|---|---|-------------|----------------|----------------|----------|
| 01  | CIRT | 54     | 70      | Oral cavity | SCC  | Postop  | 4 | 0 | 0 | 2 | 1.0 | 75.0        | 129.0          | 167.9       |          |
| 02  | CIRT | 57     | 90      | Nasopharynx | SCC  | Def     | 2 | 0 | 0 | 2 | 0.7 | 63.8        | 137.8          | 30.6        |          |
| 03  | CIRT | 61     | 90      | Hypopharynx | SCC  | Def     | 4 | 0 | 0 | 3 | 3.6 | 63.8        | 123.8          | 84.0        |          |
| 04  | VMAT | 72     | 80      | Sinuses     | SCC  | Def     | 4 | 0 | 0 | 2 | 1.0 | 60.0        | 126.0          | 110.0       |          |
| 05  | CIRT | 73     | 70      | Oral cavity | MEC  | Def     | 4 | 0 | 0 | 3 | 1.0 | 67.5        | 147.5          | 25.0        |          |
| 06  | VMAT | 71     | 80      | Oropharynx  | SCC  | Def     | 4 | 0 | 0 | 2 | 7.2 | 60.0        | 123.0          | 65.0        |          |
| 07  | VMAT | 54     | 80      | Nasopharynx | SCC  | Def     | 1 | 2 | 0 | 3 | 4.5 | 60.0        | 124.0          | 54.7        |          |
| 08  | CIRT | 54     | 90      | Sinuses     | AC   | Postop  | 3 | 0 | 0 | 2 | 1.6 | 67.5        | 127.5          | 49.3        |          |
| 09  | VMAT | 52     | 80      | Skull base  | AC   | def     | 4 | 0 | 0 | 3 | 0.9 | 60.0        | 130.0          | 10.4        |          |
| 10  | VMAT | 49     | 80      | Nasopharynx | SCC  | def     | 4 | 0 | 0 | 3 | 3.3 | 60.0        | 124.0          | 31.7        |          |
| 11  | VMAT | 65     | 80      | Nasal cavity | SCC  | Def     | 3 | 0 | 0 | 3 | 4.0 | 60.0        | 130.0          | 37.4        |          |
| 12  | VMAT | 55     | 80      | Nasal cavity | SCC  | Postop  | 3 | 0 | 1 | 1 | 2.1 | 60.0        | 120.0          | 25.6        |          |
| 13  | CIRT | 62     | 70      | Oral cavity | SCC  | Def     | 3 | 0 | 0 | 2 | 8.3 | 63.8        | 137.8          | 42.4        |          |
| 14  | CIRT | 69     | 70      | Oral cavity | SCC  | Def     | 4 | 0 | 0 | 3 | 2.8 | 63.8        | 138.8          | 196.4       |          |
| 15  | CIRT | 50     | 90      | Nasal cavity | SCC  | Def     | 4 | 0 | 0 | 2 | 3.2 | 63.8        | 129.8          | 139.6       |          |
| 16  | CIRT | 69     | 80      | Oropharynx  | SCC  | Def     | 4 | 0 | 0 | 3 | 17.9| 67.5        | 133.5          | 42.6        |          |

CIRT carbon ion radiotherapy, VMAT volumetric modulated arc therapy, KPS Karnofsky Performance Score, EQD2 equivalent dose in 2 Gy fractions, ReRT re-radiotherapy, GTV gross tumor volume, CTV clinical target volume, PTV planning target volume, f female, m male, SCC squamous cell carcinoma, MEC mucoepidermoid carcinoma, AC adenocarcinoma
12.0%) and the optic chiasma (−6.1 Gy EQD2; 10.2%). Also, the mean dose to the optic nerves and ipsilateral eye was reduced by 8.8 and 9.8%, respectively. Cumulative mean dose-volume histograms for all regions of interest are shown in Fig. 2. Further data is shown in the appendix (Additional file 1: Tab. S4). A clinical case example of a patient with nasal cavity recurrence is shown in Fig. 3.

Several patients had tumors in close proximity or with direct infiltration of these OARs. In a total of three patients, adherence to ipsilateral optic nerve dose constraints was not possible. All three patients decided to accept increased toxicity risks for maximum tumor control probability. Adherence to clinical constraints was comparable with both RT modalities, as summarized in the appendix (Additional file 1: Tab. S5).
Pattern of local failure analysis

Local failure occurred in 9/14 evaluable patients (64%) within six months after reirradiation. Two of these patients had parallel nodal or distant failure. The most frequent salvage treatment was immunotherapy (67%), followed by salvage-surgery and best supportive care. The mean rGTV was 8.1 ccm (range 1.6–17.5 ccm). The intricacy of local failure evaluation is summarized in Table 2 as a basis for all clinical scenarios available in the appendix (Additional file 1: Fig. 5–13).

In all nine patients with local failure, in total twelve rGTVs were contoured since three patients had more than one type of local failure simultaneously. The most frequent local failure was type E (n = 6; 50%), followed by type B (n = 4; 33%) and type A (n = 2; 17%). Most rGTV centroids of type E local failures were localized outside CTV + 5 mm (n = 5; 83%). Possible causes of type E local failure were aberrant areas of recurrence (n = 5; 83%) or improper risk assessment (n = 1; 17%). Patients with type B local failure had either overgrown recurrence (n = 3; 75) or dosimetric failure (n = 1; 25%). Potential causes of type A local failure were biological and/or dosimetric failure. Dose recalculation with mMKM in both patients with type A local failure after CIRT revealed significantly reduced rGTV Dmean and rGTV D95% in one patient. A clinical case example of mMKM dose recalculation in a patient with type A failure after CIRT is shown in Fig. 4. Further clinical case examples of all other patients are shown in the appendix.

Discussion

The biophysical properties of CIRT translated into clinical dose-volume advantages both in the target volume and OAR across all reirradiation scenarios compared to VMAT. Local failure pattern analysis revealed further CIRT specific clinical benefits and potential pitfalls in patients with recurrent head and neck cancer.

Adding on to the complex reirradiation setting, the patient cohort included primarily unfavorable high-grade tumors (63%) with a mean GTV of 29 ccm. The target prescription dose was superior with CIRT compared to VMAT (CTV Dmean: 63.6 vs. 60.2 Gy EQD2; +5.6%; p < 0.001). In general, reirradiation tumor control is dosedependent and significantly inferior with a prescribed dose ≤60 Gy [24]. However, reirradiation with ≥68 Gy is associated with excessive toxicity, thereby resulting in decreased survival rates compared to 60 Gy [25]. In our study, most patients (n = 12; 75%) were treated within the recommended range of 60–66 Gy [7] prescription dose and some above (n = 4; 100% CIRT; Dmean 69.4 Gy
EQD2). CIRT may enable further dose escalation without increasing side effects due to its biophysical advantages compared to VMAT, but outcome evaluation is pending. In comparison to squamous cell carcinoma (SCC), dose escalation effects may have more pronounced impact on tumor control in radioresistant tumors such as adenoid cystic carcinomas [26, 27]. Moreover, the previously described risk of severe soft-tissue necrosis [28] in the CIRT high-dose area of the previously irradiated target remains problematic. In recurrent SCC, the impact of moderate hypofractionated CIRT compared to normofractionated VMAT on tumor control and normal tissue complication probability (NTCP) has yet to be determined in randomized clinical trials.

Despite the increased target dose, CIRT resulted in significantly reduced OAR dose across all patients (−8.7% Dmean) compared to VMAT. Reirradiation NTCPs have yet to be determined in clinical trials, considering previous sequelae, the radiation interval and cumulative dose-volume metrics. The toxicity profiles as the primary endpoint of the CARE trial will therefore be analyzed after completion of the study. Previous dosimetric comparisons of proton RT and VMAT have shown clinical benefits with similar mean dose reductions [29, 30] and NTCPs could be even more dose-dependent in the reirradiation setting. On the other hand, for OAR close to the target, EQD2 reduction by CIRT is attenuated due to hypofractionation compared to normofractionated VMAT.

The dose-volume benefits were most pronounced in the brainstem (−20.7% Dmax) and the optic chiasma (−13.0% Dmax) with CIRT compared to VMAT. The mean dose to the ipsilateral and contralateral inner ear (−11.3%/−13.7%), eye (−9.8%/−4.2%) and optic nerve (−8.8%/−9.0%) was also advantageous with CIRT. These dose-limiting OAR are decisive for the treatment option of reirradiation but with exception of the brainstem and spinal cord, a risk–benefit-tradeoff is frequently inevitable [17]. In the current study, the clinical goal of the ipsilateral optic nerve (81.3% vs. 75.0%) was reached slightly
Table 2  Local failure pattern analysis after reirradiation with CIRT vs. VMAT in recurrent head and neck cancer

| Pat | ReRT | Failure type | rGTV (ccm) | rGTV Dmean | rGTV D95% | rGTVc Dmean | N failure | M failure | Possible cause of local failure | Salvage treatment |
|-----|------|--------------|------------|------------|-----------|-------------|-----------|-----------|--------------------------------|------------------|
| 01  | CIRT | E            | 15.9       | 5.7        | 19.4      | No          | No        | Aberrant areas of recurrence | Best supportive care |
| 02  | CIRT | E            | 4.4        | 1.3        | 2.8       | No          | No        | Aberrant areas of recurrence | Immunotherapy    |
| 03  | CIRT | A            | 1.6        | 63.8       | 62.8      | 63.6        | No        | No        | Biological/dosimetric failure | Salvage surgery  |
| 04  | VMAT | B and E      | 4.6        | 59.1/35.3  | 53.3/10.7 | 60.4/36.2   | No        | No        | Overgrown recurrence + aberrant areas of recurrence | Immunotherapy    |
| 08  | CIRT | E            | 5.4        | 42.1       | 6.9       | 57.9        | Yes       | Yes       | Improper risk assessment    | Salvage surgery  |
| 09  | VMAT | E            | 6.6        | 16.5       | 6.2       | 13.4        | No        | No        | Aberrant areas of recurrence | Chemotherapy      |
| 10  | VMAT | B            | 2.2        | 37.4       | 15.0      | 38.9        | Yes       | No        | Dosimetric failure           | Chemotherapy      |
| 14  | CIRT | A and B      | 14.8       | 63.8/59.5  | 62.8/45.9 | 63.5/63.0   | No        | No        | Biological/dosimetric failure + overgrown recurrence | Immunotherapy    |
| 15  | CIRT | B and E      | 17.5       | 59.8/0     | 36.3/0    | 63.1/0      | No        | No        | Overgrown recurrence + aberrant areas of recurrence | Immunotherapy    |

CIRT Carbon ion radiotherapy, VMAT volumetric modulated arc therapy, RT Radiotherapy, rGTV Recurrence gross tumor volume, Dmean Mean dose, D95% Dose reached in 95% of the rGTV, rGTVc rGTV centroid, N nodal, M metastatic
more often with CIRT. In line with previous studies on particle therapy [31], the dose reduction was particularly noticeable for the contralateral side with regard to paired OAR (Additional file 1: Tab. S3). The difference in maximum dose did not reach significance for the ipsilateral optic nerve, mandible, brain and ipsilateral eye, due to proximity to the target volume. Other dose-volume metrics (e.g. D1cc) could be more relevant for CIRT in certain clinical scenarios where the high-LET target region is very close to vital OAR.

The pattern of local failure analysis revealed primarily extraneous dose failures (50%), mostly caused by possible aberrant areas of recurrence. Tissue changes from previous local therapies strongly impede target volume

![Image](https://example.com/image.png)

**Fig. 4** 69-year-old female patient with recurrent oral cavity cancer treated with 51 Gy (RBE) CIRT (A) around 28 years after prior radiotherapy with 75 Gy. CIRT yielded significant clinical benefits w.r.t. the brainstem (−47.5% Dmax), ipsilateral optic nerve (−16.8% Dmax), ipsilateral eye (−21.3% Dmean) and contralateral inner ear (−23.2% Dmean) compared to VMAT (B). The patient developed type A local failure, delineated on the planning CT (A), caused biological and/or dosimetric failure. Dose recalculation with the modified microdosimetric model w.r.t. the type A failure revealed significantly reduced rGTV Dmean and rGTV D95% dose EQD2 compared to the local effect model I (C–D).
delineation in recurrent head and neck cancer. Combining multi-modality imaging including CT, diffusion-weighted MRI and positron emission tomography (PET)/CT can be crucial to mitigate uncertainties in contouring [32, 33]. One patient with type E local failure developed tumor recurrence within 5 mm of the CTV. Due to concerns regarding toxicity, the CTV margin was kept at 3 mm instead of 5 mm, as recommended in the consensus guidelines [7], thereby possibly causing local failure. In patients with type B local failure, the rate of overgrown recurrence could be reduced by improved image-guidance [34], in particular for CIRT. Since the start, ion beam image-guidance was based on daily orthogonal X-rays and weekly CT scans only in selected patients, possibly detecting aggressive tumor growth too late. Current and future perspectives in image-guided adaptive particle therapy, focused on CT/MR imaging [35], can eliminate type B failures caused by overgrown recurrence and provide functional response assessment. In addition, robustness of CIRT can be improved by state-of-the-art image-guidance, mitigating range uncertainties caused by anatomical changes. One type B local failure after VMAT was caused by dosimetric failure, due to proximity to the brainstem. The CIRT treatment plan was non-superior in this scenario, due to the direct spatial relationship of target volume and OAR.

Type A local failure occurred twice after CIRT, potentially caused by dosimetric and/or biological failure in both patients. In one patient the rGTV was located adjacent to a lower jaw metal implant, which potentially caused range uncertainties. In the other patient with hypopharyngeal recurrence, organ motion with changing air/tissue interface possibly deteriorated the dose distribution in the target volume. Moreover, α/β value of 2 Gy may lead to relative underdosage in the target, in particular for patients with SCC (α/β ~ 10 Gy) [36]. Nonetheless, mMKM dose recalculation revealed significantly reduced Dmean and D95% in the rGTV, compared to LEM 1, in one patient. These findings advocate further comparisons of RBE-models for CIRT to mitigate RBE uncertainties in the target volume and OAR within the ongoing CARE study. The clinical potential of CIRT is not reached yet. Several further research endeavors, e.g. multi-ion RT [37], hadron arc RT [38], and ultra-high dose rate CIRT [39], aim to further optimize biological effects for the best of the patient.

The current study had several limitations. First, the sample size was rather small, requiring further investigations as part of the CARE study. Second, the PTV is defined slightly different and dose fractionation schemes varied according to treatment group. Third, according to the clinical standard for CIRT at our institution, the α/β value was equal for the tumor and OAR, thereby underestimating radiobiological factors. Furthermore, the conversion of CIRT biological dose in EQD2 using the α/β used as input is an approximation not considering the local α and β values originating from the mixed radiation field of CIRT [40]. Nonetheless, the current study is the first to compare CIRT to VMAT as part of a randomized prospective trial, thereby increasing the body of evidence with relevant clinical data.

Conclusions

Both VMAT and CIRT are feasible techniques for reirradiation of recurrent head and neck cancer. CIRT resulted in highly improved critical OAR sparing compared to VMAT across all head and neck cancer reirradiation scenarios despite an increased prescription dose. Pattern of local failure analysis revealed potential clinical pitfalls with regard to image-guidance and biological dose-optimization. Therefore, continued investigations within the CARE study will consider novel imaging and dose recalculation strategies for treatment planning.

Abbreviations

AC: Adenocarcinoma; CIRT: Carbon ion radiotherapy; CT: Computed tomography; CTV: Clinical target volume; EQD2: Equivalent dose in 2 Gy fractions; GTV: Gross tumor volume; KPS: Karnofsky Performance Score; LEM: Local effect model; LET: Linear energy transfer; MEC: Mucoepidermoid carcinoma; mMKM: Modified microdosimetric kinetic model; MRI: Magnetic resonance imaging; NTCP: Normal tissue complication probability; OAR: Organ at risk; PET: Positron emission tomography; PTV: Planning target volume; RBE: Relative biological effectiveness; rGTV: Recurrent macroscopic tumor; ReRT: Reirradiation; RT: Radiotherapy; SCC: Squamous cell carcinoma; VMAT: Volume modulated arc therapy.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13014-022-02093-4.

Additional file 1: Tab. S3. Target dose-volume comparison of reirradiation with CIRT vs. VMAT in recurrent head and neck cancer. Relative dose differences are specified in percent of 60 Gy equivalent dose in 2 Gy fractions. Tab. S4. Organs at risk dose-volume comparison of reirradiation with CIRT vs. VMAT in recurrent head and neck cancer. Relative dose differences are specified in percent of 60 Gy equivalent dose in 2 Gy fractions. Tab. S5. Clinical goals comparison of reirradiation with CIRT vs. VMAT in recurrent head and neck cancer. Fig. S5. 57-year-old male patient with recurrent nasopharyngeal cancer treated with 51 Gy (RBE) CIRT (D–F) around 0.7 years after prior radiotherapy with 74 Gy. CIRT yielded significant clinical benefits w.r.t. the spinal cord (~29% ΔDmax) compared to VMAT (A–C). The patient developed type E local failure (> CTV + 5 mm), delineated on the planning CT (D–F), caused by aberrant areas of recurrence. Fig. S6. 72-year-old female patient with recurrent paranasal sinus cancer treated with 60 Gy VMAT (A–C) around 1 year after prior radiotherapy with 66 Gy. CIRT (D–F) yielded significant clinical benefits w.r.t. the brainstem (~19.7% ΔDmax), ipsilateral eye (~27.0% ΔDmax) and ipsilateral inner ear (~13.3% ΔDmean). The patient developed type B and E (> CTV + 5 mm) local failure, delineated on the planning CT (A–C), caused by overgrown recurrence and aberrant areas of recurrence. Fig. S7. 54-year-old male patient with recurrent nasopharyngeal cancer treated with 60 Gy VMAT (A–C) around 4.5 years after prior radiotherapy with 64 Gy. CIRT (D–F) yielded significant clinical benefits w.r.t. the brainstem (~37.0% ΔDmax), ipsilateral inner ear (~26.8% ΔDmean) and contralateral...
inner ear (−20.2% Dmean). The patient developed no local failure during follow-up. **Fig. S8.** 54-year-old male patient with recurrent paranasal sinus cancer treated with 54 Gy (RBE) CIRT (D–F) around 1.6 years after prior radiotherapy with 60 Gy. CIRT yielded significant clinical benefits w.r.t. the brainstem (−43.5% Dmax) and the contralateral eye (−17.7% Dmax) compared to VMAT (A–C). The patient developed type B local failure (≤ CTV + 5 mm), delineated on the planning CT (D–F), caused by improper risk assessment. **Fig. S9.** 52-year-old female patient with skull base recurrence treated with 60 Gy VMAT (A–C) around 1 year after prior radiotherapy with 70 Gy. CIRT (D–F) yielded significant clinical benefits w.r.t. the ipsilateral inner ear (−13.8% Dmean) and the optic chiasma (−13.5% Dmax) but not the brainstem (−2.2% Dmax). The patient developed type C local failure (≤ CTV + 5 mm), delineated on the planning CT (A–C), caused by aberrant areas of recurrence. **Fig. S10.** 50-year-old male patient with recurrent nasopharyngeal cancer treated with 60 Gy VMAT (A–C) around 3.3 years after prior radiotherapy with 64 Gy. CIRT (D–F) yielded significant clinical benefits w.r.t. the optic chiasma (−50.7% Dmax), ipsilateral optic nerve (−29.3% Dmax) and ipsilateral inner ear (−28.0% Dmean). The patient developed type B local failure, delineated on the planning CT (A–C), caused by dosimetric failure due to direct contact of the tumor to the brainstem. CIRT was non-superior with regard to gross tumor volume coverage next to the brainstem. **Fig. S11.** 61-year-old male patient with hypopharyngeal recurrence treated with 51 Gy (RBE) CIRT (D–F) around 3.6 years after previous radiotherapy with 60 Gy. CIRT yielded significant clinical benefits w.r.t. the spinal cord (−23.8% Dmax) compared to VMAT (A–C). The patient developed type A local failure in the central high-dose-region of the CT; caused by biological and/or dosimetric failure. The recurrent tumor (IGTV) and its centroid were delineated in black/red and mapped to the planning CT (D–F). Dose recalculation with the modified microdosimetric model showed no relevant changes compared to the local effect model. **Fig. S12.** 50-year-old male patient with recurrent nasal cavity cancer treated with 51 Gy (RBE) CIRT (D–F) around 1.2 years after prior radiotherapy with 66 Gy. CIRT yielded significant clinical benefits w.r.t. the spinal cord (−25.8% Dmax) but not the mandible (−7.8% Dmax), −10.2% Dmean) compared to VMAT (A–C). The patient developed no local failure during follow-up.

Acknowledgements
We acknowledge Eric Tonndorf-Martini and Thomas Mielke for treatment planning as well as Dr. Cornelia Jakel and Dr. Adriane Hommertgen for coordination of the CARE study. We thank the study team for conducting the trial.

Author contributions
T.H.: Data curation, statistical analysis, investigation, validation, methodology, visualization, writing original draft, writing review, editing. T.T.: Data curation, statistical analysis, investigation, validation, methodology, visualization, writing review, editing. H.F., S.R., L.B., and K.W.: Data curation, investigation, validation, methodology, project administration, supervision, writing review, editing. S.A.: Data curation, investigation, validation, methodology, writing review, editing, project administration, supervision. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. We acknowledge financial support by Deutsche Forschungsgemeinschaft within the funding programme Open Access Publikationskosten as well as by Heidelberg University. The current study received major funding within a competitive and peer-review research grant financed by Deutsche Krebshilfe. T.H. and S.R. are funded by the Physician-Scientist Program of Heidelberg University, Faculty of Medicine (Grant No. 70113618).

Availability of data and materials
The data that support the findings of this study are available from the corresponding author on reasonable request.

Declarations

Ethical approval and consent to participate
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of Heidelberg University (S-708/2018). Informed consent was obtained from all subjects involved in the study.

Consent for publication
Not applicable.

Competing interests
JD reports grants from CRI The Clinical Research Institute, grants from View Ray Inc., grants from Accuray International, grants from Accuray Incorporated, grants from RaySearch Laboratories AB, grants from Vision RT limited, grants from Merck Serono GmbH, grants from Astellas Pharma GmbH, grants from Astra Zeneca GmbH, grants from Siemens Healthcare GmbH, grants from Solution Akademie GmbH, grants from Eromed PLC Surrey Research Park, grants from Quintiles GmbH, grants from Pharmaceutical Research Associates GmbH, grants from Boehinger Ingelheim Pharma GmbH Co, grants from PTW-Friedberg Dr. Pychlauf GmbH, grants from Nanobiotix A.A., outside the submitted work. The other authors declare no conflict of interest. SA reports grants from Novocure Inc., Accuray International Sàrl, Merck Sharp & Dohme, Sanofi-Aventis GmbH and Merk-Serono GmbH outside the submitted work. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Author details
1 Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. 2 Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. 3 National Center for Tumor Diseases (NCT), Heidelberg, Germany. 4 Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 5 Heidelberg Ion Beam Therapy Center (HIT), Heidelberg, Germany. 6 German Cancer Consortium (DKTK), partner site Heidelberg, German Cancer Research Center (DKFZ), Heidelberg, Germany. 7 Medical Physics, National Centre of Oncological Hadrontherapy (CNAO), Pavia, Italy.

Received: 27 March 2022 Accepted: 30 June 2022
Published online: 08 July 2022

References
1. Durante M, Debus J, Loeffler JS. Physics and biomedical challenges of cancer therapy with accelerated heavy ions. Nat Rev Phys. 2021;3(12):777–90.
2. Seidensaul K, Harrabi SB, Uhl M, Debus J. Re-irradiation with protons or heavy ions with focus on head and neck, skull base and brain malignancies. Br J Radiol. 2020;93(1107):20190516.
3. Held T, Lang K, Regnery S, Weusthof K, Hommertgen A, Jakel C, Tonndorf-Martini E, Krismam J, Plienkt P, Zaoui K, et al. Carbon ion re-irradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial. Radiat Oncol. 2020;15(1):1–8.
4. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spano S, Rotman M, Meredith R, Ang KK. Final report of RTDG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30(3):281–8.
5. Langer CJ, Harris J, Horwitz EM, Nicolau N, Kies M, Cursen W, Wong S, Ang K. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007;25(30):4800–5.
6. Vargo JA, Ward MC, Caudell JJ, Riaz N, Dunlap NE, Irow D, Zakem SJ, Dault J, Awan MJ, Higgins KA, et al. A multi-institutional comparison of SBRT and IMRT for definitive reirradiation of recurrent or second primary head and neck cancer. Int J Radiat Oncol Biol Phys. 2018;100(3):595–605.

7. Ng WT, Soong YL, Ahn YC, AlHussain H, Choi HCW, Corry J, Grégoire V, Harrington KJ, Hu CS, Jensen K, et al. International recommendations on reirradiation by intensity modulated radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2021;110(3):682–95.

8. Romesser PB, Cahlon O, Scher ED, Sine K, DeSelm C, Fox JL, Mah D, Garg MK, Han-Chih Chang J, et al. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Biol Phys. 2016;95(1):386–95.

9. Hayashi K, Koto M, Iwaka H, Hagiwara Y, Tsuji H, Ogaawa K, Kamata T. Feasibility of re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy. Radiother Oncol. 2019;136:48–53.

10. Held T, Windsch P, Akkaba S, Lang K, El Shafie R, Bernhardt D, Plinkert P, Kargus S, Rieken S, Herfarth K, et al. Carbon ion reirradiation for recurrent head and neck cancer: a single-institutional experience. Int J Radiat Oncol Biol Phys. 2019;105(4):803–11.

11. Karger CP, Peschke P. RBE and related modeling in carbon-ion therapy. Phys Med Biol. 2017;63(1):10120.

12. Scholz M, Kargus S, G. G. Crust structure and the calculation of biological effects of heavy charged particles. Adv Space Res. 1996;18(1–2):215–4.

13. Grün R, Friedrich T, Elsässer T, Krämer M, Zink K, Karger CP, Durante M, Haberer T, Debus J, Kuhn S, Hartmann GH. Three-dimensional dose calculations in carbon ion therapy. Med. Phys. 2001;49(5):1493–504.

14. Inaniwa T, Furukawa T, Kase Y, Matsuufuji N, Toshito T, Matsumoto Y, Furusawa Y, Noda K. Treatment planning for a scanned carbon beam with a modified microdosimetric kinetic model. Phys Med Biol. 2010;55(22):6721–37.

15. Mein S, Klein C, Kopp B, Magro G, Harrabi S, Karger CP, Haberer T, Debus J, Abboldali A, Dokic I, et al. Assessment of RBE-weighted dose models for carbon ion therapy toward modernization of clinical practice at HIT. In vivo, in vivo, and in patients. Int J Radiat Oncol Biol Phys. 2020;108(3):779–91.

16. Brouwer CL, Steenbakkers RJ, Bourhis J, Dudach G, Grau C, Grégoire V, van Herk M, Lee A, Maingon P, Nutting C, et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKN-PCS, NCIC-CTG, NCI, NRG Oncology and TROG consensus guidelines. Radiat Oncol. 2015;11(7):83–90.

17. Held T, Harrabi SB, Lang K, Akkaba S, Windsch P, Bernhardt D, Rieken S, Herfarth K, Debus J, Abegeberg S. Dose-limiting organs at risk in carbon ion re-irradiation of head and neck malignancies: an individual risk-benefit tradeoff. Cancers (Basel). 2019;11(12):2016.

18. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Esbruch A, Bentzen SM, Nam J, Deasy JO. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl S10–19.

19. Weyrather WK, Kargus S, Karger CP. The alfa and beta of tumours: a review of parameters of the linear-quadratic model. Int J Radiat Oncol Biol Phys. 2019;11(3):297.

20. van Leeuwen CM, Oei AL, Crezee J, Bel A, Franken NAP, Stalpers LJA, Kok HP. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13(1):196.

21. Kopp B, Mein S, Dokic I, Harrabi S, Rohlen TT, Haberer T, Debus J, Abboldali A, Mairani A. Development and validation of single field multi-ion particle therapy treatments. Int J Radiat Oncol Biol Phys. 2020;106(1):194–205.

22. Mein S, Tessonnier T, Kopp B, Harrabi S, Abboldali A, Debus J, Haberer T, Mairani A. Spot-scanning hadron arc (SHARc) therapy: a study with light and heavy ions. Adv Radiat Oncol. 2021;6(3):100661.

23. Mohamed ASR, Rosenthal DJ, Awan MJ, Garden AS, Kocak-Uzel E, Belal AM, El-Gowily AG, Phan J, Beadle BM, Gunn GB, et al. Methodology for analysis and reporting patterns of failure in the Era of IMRT: head and neck cancer. Radiother Oncol. 2016;117(1):195.

24. Lee AW, Foo W, Law SC, Poon YF, Sze WM, Sk O, Tung SY, Lau WH. Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys. 1997;38(1):43–52.

25. Tian Y, Zhao C, Guo Y, Huang Y, Huang S-M, Deng X-W, Lin C-G, Lu T, Han F. Effect of total dose and fraction size on survival of patients with locally recurrent nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a phase 2, single-center, randomized controlled trial. Cancer. 2014;120(22):3502–9.

26. Jensen AD, Nikoghosyan AV, Poulaakis M, Höss A, Haberer T, Jäkel O, Munter MW, Schulze-Errntner D, Huber PE, Debus J. Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival. Cancer. 2015;121(17):3001–9.

27. Sulaiman NS, Demizu Y, Kato M, Saiotoh JI, Suefuji H, Tsuji H, Ohno T, Shiroyama Y, Okimoto T, Daimon T, et al. Multicenter study of carbon-ion radiotherapy for adenoid cystic carcinoma of the head and neck: subanalsyis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). Int J Radiat Oncol Biol Phys. 2018;100(3):655–66.

28. Hu J, Huang Q, Gao J, Guan X, Hu W, Yang J, Qiu X, Chen M, Kong L, Lu JJ. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma. Cancer. 2020;126(23):1713–83.

29. Blanchard P, Garden AS, Gunn GB, Rosenthal DJ, Morrison WH, Hernandez M, Cockson J, Lee JJ, Ye R, Fuller CD, et al. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer—a case matched analysis. Radiother Oncol. 2016;120(1):48–55.

30. Zhang W, Zhang X, Yang P, Blanchard P, Garden AS, Gunn B, Fuller CD, Chambers M, Hutcheson KA, Ye R, et al. Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. Radiother Oncol. 2016;123(3):401–5.

31. Romesser PB, Cahlon O, Scher ED, Zhou Y, Berry SL, Rybkin A, Sine KM, Tang S, Sherman EJ, Wong R, et al. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiother Oncol. 2016;14(18):286–92.

32. Ren J, Erikens J, Nijpakm J, Korensm S. Comparing different CT, PET and MRI multi-modality image combinations for deep learning-based head and neck tumor segmentation. Acta Oncol. 2021;60(11):1399–406.

33. Elicin O, Vollnberg B, Shelan M, Riggenbach E, Bojaxhiu B, Mathier E, Giger R, Abeersold DM, Klaeser B. Impact of pretreatment second look (18)FDG-PET/CT on stage and treatment changes in head and neck cancer. Clin Radiol. 2017;72(1):138–139.

34. Chen AM, Daly ME, Cui J, Mathai M, Benedict S, Purdy JA. Clinical outcomes among patients with head and neck cancer treated by intensity-modulated radiotherapy with and without adaptive replanning. Head Neck. 2014;36(11):1451–6.

35. Li Y, Kubota Y, Tashiro M, Ohno T. Value of three-dimensional imaging systems for image-guided carbon ion radiotherapy. Cancers (Basel). 2019;11(3):297.

36. Lee AW, Foo W, Law SC, Poon YF, Sze WM, Sk O, Tung SY, Lau WH. Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys. 1997;38(1):43–52.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.